




RealRate

PHARMACEUTICAL 2014

Phio Pharmaceuticals Corp
Rank 139 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Phio Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phio Pharmaceuticals Corp compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Phio Pharmaceuticals Corp is the variable Research and Development, reducing the Economic Capital Ratio by 112% points.

The company's Economic Capital Ratio, given in the ranking table, is 217%, being 26% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	14,743
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,076
Liabilities, Non-Current	0
Other Assets	18
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	24
Other Revenues	399
Property and Equipment	177
Research and Development	17,651
Selling, General and Administrative Expense	3,697

Output Variable	Value in 1000 USD
Assets	14,938
Liabilities	2,076
Expenses	21,348
Revenues	399
Stockholders Equity	12,862
Net Income	-20,925
Comprehensive Net Income	-20,925
BaseVar	19,392
ECR before Limited Liability	84%
Economic Capital Ratio	217%